Filing Flows › Elite Pharmaceuticals (ELTP) › Q4 FY26 › vs Q4 FY25
Elite Pharmaceuticals (ELTP) Q4 FY26 vs Q4 FY25 (year over year)
Elite Pharmaceuticals's revenue rose $8.8M (+27%) from $32.0M in Q4 FY25 to $40.7M in Q4 FY26. Gross margin 51.0% against 54.1% (-3.1 pts).
Elite Pharmaceuticals, Q4 FY26: revenue $40.7M (+27% year over year), operating margin 25.0%, net earnings $18.5M, operating cash flow $9.1M. The chart draws each line against Q4 FY25, the increases inside each band.
Margins
| Q4 FY26 | Q4 FY25 | Change | |
|---|---|---|---|
| Gross margin | 51.0% | 54.1% | -3.1 pts |
| Operating margin | 25.0% | 34.9% | -9.9 pts |
| Net margin | 45.3% | 53.1% | -7.8 pts |
| Free cash flow margin | 21.5% | 9.9% | +11.6 pts |
Every line
| Line | Q4 FY26 | Q4 FY25 | Change | % |
|---|---|---|---|---|
| Revenue | $40.7M | $32.0M | $8.8M | +27% |
| Gross profit | $20.8M | $17.3M | $3.5M | +20% |
| Cost of revenue | $20.0M | $14.7M | $5.3M | +36% |
| Other income, net | $10.7M | $8.1M | $2.5M | +31% |
| Operating profit | $10.2M | $11.2M | −$967K | -9% |
| Operating expenses | $10.6M | $6.1M | $4.4M | +72% |
| Pre-tax earnings | $20.9M | $19.3M | $1.6M | +8% |
| Research & development | $1.6M | $2.0M | −$399K | -20% |
| General & admin | $7.7M | $2.0M | $5.7M | +278% |
| Other operating costs | $1.2M | $2.1M | −$819K | -40% |
| Net earnings | $18.5M | $17.0M | $1.5M | +9% |
| Income tax | $2.4M | $2.3M | $119K | +5% |
| Depreciation & amortization | $252K | $826K | −$574K | -69% |
| Share-based compensation | $29K | $52K | −$23K | -44% |
| Working capital & other | $9.6M | $14.0M | −$4.4M | -31% |
| Operating cash flow | $9.1M | $3.9M | $5.2M | +133% |
| Free cash flow (OCF − capex) | $8.7M | $3.2M | $5.6M | +177% |
| Capital expenditures | $398K | $754K | −$356K | -47% |
Questions
How much did Elite Pharmaceuticals's revenue grow year over year in Q4 FY26?
Elite Pharmaceuticals's revenue rose $8.8M (+27%) from $32.0M in Q4 FY25 to $40.7M in Q4 FY26. Gross margin 51.0% against 54.1% (-3.1 pts).